SG11201601461RA - Pharmaceutical composition containing pyrimidine compound as active ingredient - Google Patents
Pharmaceutical composition containing pyrimidine compound as active ingredientInfo
- Publication number
- SG11201601461RA SG11201601461RA SG11201601461RA SG11201601461RA SG11201601461RA SG 11201601461R A SG11201601461R A SG 11201601461RA SG 11201601461R A SG11201601461R A SG 11201601461RA SG 11201601461R A SG11201601461R A SG 11201601461RA SG 11201601461R A SG11201601461R A SG 11201601461RA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- active ingredient
- composition containing
- pyrimidine compound
- containing pyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013176355 | 2013-08-28 | ||
| PCT/JP2014/072349 WO2015030021A1 (fr) | 2013-08-28 | 2014-08-27 | Composition pharmaceutique ayant un composé pyrimidine comme principe actif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601461RA true SG11201601461RA (en) | 2016-03-30 |
Family
ID=52586573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601461RA SG11201601461RA (en) | 2013-08-28 | 2014-08-27 | Pharmaceutical composition containing pyrimidine compound as active ingredient |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160199371A1 (fr) |
| EP (1) | EP3040072A4 (fr) |
| JP (1) | JPWO2015030021A1 (fr) |
| KR (1) | KR20160040719A (fr) |
| CN (1) | CN105492009A (fr) |
| AR (1) | AR097455A1 (fr) |
| AU (1) | AU2014312919A1 (fr) |
| CA (1) | CA2922352A1 (fr) |
| HK (1) | HK1219432A1 (fr) |
| IL (1) | IL244206A0 (fr) |
| MX (1) | MX2016002589A (fr) |
| PH (1) | PH12016500372A1 (fr) |
| RU (1) | RU2016106774A (fr) |
| SG (1) | SG11201601461RA (fr) |
| TW (1) | TW201605452A (fr) |
| WO (1) | WO2015030021A1 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| WO2014026125A1 (fr) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Dérivés de pyrazine en tant qu'inhibiteurs de fgfr |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| AU2014337291B9 (en) | 2013-10-18 | 2020-05-07 | Eisai R&D Management Co., Ltd. | Pyrimidine FGFR4 inhibitors |
| ES2682493T3 (es) | 2013-10-25 | 2018-09-20 | Novartis Ag | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de FGFR4 |
| US20180185341A1 (en) | 2014-10-03 | 2018-07-05 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| MX2017013248A (es) | 2015-04-14 | 2018-07-06 | Eisai R&D Man Co Ltd | Compuesto del inhibidor fgfr4 cristalino y usos del mismo. |
| EP3454898B1 (fr) | 2016-05-10 | 2021-11-10 | Eisai R&D Management Co., Ltd. | Associations médicamenteuses permettant de réduire la viabilité et/ou la prolifération cellulaire |
| CN107541495B (zh) * | 2016-06-28 | 2022-04-26 | 上海市东方医院 | 一种fgf19过表达的人肝癌细胞系及其应用 |
| WO2018055503A1 (fr) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combinaison comprenant un antagoniste de pd-1 et un inhibiteur de fgfr4 |
| PL3534902T3 (pl) | 2016-11-02 | 2023-03-27 | Novartis Ag | Skojarzenia inhibitorów fgfr4 i sekwestrantów kwasów żółciowych |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019213544A2 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
| CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
| WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
| WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3162010A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derives d'un inhibiteur de fgfr |
| EP4069696A1 (fr) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20230172867A1 (en) * | 2020-05-15 | 2023-06-08 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
| CA3220274A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2600531A1 (fr) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Composes de pyrimidine et methodes d'utilisation |
| US20070161645A1 (en) | 2005-11-02 | 2007-07-12 | Targegen, Inc. | Thiazole inhibitors targeting resistant kinase mutations |
| US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
| EP2821402B1 (fr) * | 2012-02-28 | 2019-08-21 | Astellas Pharma Inc. | Composé hétérocyclique aromatique contenant de l'azote |
| PT2824181T (pt) * | 2012-03-08 | 2018-12-20 | Astellas Pharma Inc | Novo produto de fusão de fgfr3 |
-
2014
- 2014-08-26 AR ARP140103193A patent/AR097455A1/es unknown
- 2014-08-26 TW TW103129371A patent/TW201605452A/zh unknown
- 2014-08-27 US US14/914,955 patent/US20160199371A1/en not_active Abandoned
- 2014-08-27 CN CN201480047119.2A patent/CN105492009A/zh active Pending
- 2014-08-27 RU RU2016106774A patent/RU2016106774A/ru not_active Application Discontinuation
- 2014-08-27 AU AU2014312919A patent/AU2014312919A1/en not_active Abandoned
- 2014-08-27 WO PCT/JP2014/072349 patent/WO2015030021A1/fr active Application Filing
- 2014-08-27 JP JP2015534246A patent/JPWO2015030021A1/ja active Pending
- 2014-08-27 CA CA2922352A patent/CA2922352A1/fr not_active Abandoned
- 2014-08-27 EP EP14840047.6A patent/EP3040072A4/fr not_active Withdrawn
- 2014-08-27 KR KR1020167007640A patent/KR20160040719A/ko not_active Application Discontinuation
- 2014-08-27 MX MX2016002589A patent/MX2016002589A/es unknown
- 2014-08-27 SG SG11201601461RA patent/SG11201601461RA/en unknown
-
2016
- 2016-02-21 IL IL244206A patent/IL244206A0/en unknown
- 2016-02-24 PH PH12016500372A patent/PH12016500372A1/en unknown
- 2016-06-29 HK HK16107576.9A patent/HK1219432A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3040072A1 (fr) | 2016-07-06 |
| EP3040072A4 (fr) | 2017-03-29 |
| AU2014312919A1 (en) | 2016-03-10 |
| RU2016106774A (ru) | 2017-10-03 |
| JPWO2015030021A1 (ja) | 2017-03-02 |
| CN105492009A (zh) | 2016-04-13 |
| WO2015030021A1 (fr) | 2015-03-05 |
| HK1219432A1 (zh) | 2017-04-07 |
| TW201605452A (zh) | 2016-02-16 |
| KR20160040719A (ko) | 2016-04-14 |
| US20160199371A1 (en) | 2016-07-14 |
| CA2922352A1 (fr) | 2015-03-05 |
| AR097455A1 (es) | 2016-03-16 |
| MX2016002589A (es) | 2016-06-14 |
| PH12016500372A1 (en) | 2016-05-02 |
| IL244206A0 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244206A0 (en) | A pharmaceutical preparation containing a pyrimidine compound as an active ingredient | |
| ZA201406866B (en) | Herbicidal composition comprising uracil compound as active ingredient | |
| HK1211209A1 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
| RS59756B1 (sr) | Kombinovana farmaceutska kompozicija | |
| EP3082817A4 (fr) | Compositions pour administration de médicaments | |
| EP3036231A4 (fr) | Composés de pyrimidine substituée, compositions et applications médicinales correspondantes | |
| PL3043778T3 (pl) | Kompozycje farmaceutyczne zawierające refametinib | |
| HK1215191A1 (zh) | 低劑量醫藥組合物 | |
| HK1205462A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| HK1213182A1 (zh) | 外用藥物組合物 | |
| EP3037090A4 (fr) | Composition contenant un composé monoacétyldiglycéride en tant que principe actif pour la prévention ou le traitement de l'arthrite rhumatoïde | |
| EP2990038A4 (fr) | Composition pharmaceutique solide | |
| HUE043804T2 (hu) | Kristályos macitentánt tartalmazó gyógyászati készítmény | |
| EP2990039A4 (fr) | Composition pharmaceutique solide | |
| EP3037092A4 (fr) | Composition contenant un composé monoacétyldiglycéride en tant que principe actif pour l'inhibition du cancer du sang ou de métastase | |
| IL240875A0 (en) | Heterocyclic compounds and pharmaceutical preparations containing them | |
| HK1243927A1 (zh) | 含有茶皂醇衍生物作爲活性成分的組合物 | |
| IL249010A0 (en) | A pharmaceutical preparation containing a pyrazine carboxamide compound as an active ingredient | |
| IL243223B (en) | History of imidazole, their preparation and pharmaceutical preparations containing them | |
| EP2871187A4 (fr) | Nouveau composé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique le contenant à titre de principe actif | |
| HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
| PL3041837T3 (pl) | Kryształ o specyficznym pokroju kryształu i kompozycja farmaceutyczna zawierająca ten kryształ jako składnik czynny | |
| PL3043791T3 (pl) | Środek przeciwnowotworowy zawierający związek aminoacetonitrylowy jako substancję czynną | |
| EP2883546A4 (fr) | Nouvelle composition pharmaceutique à libération différentielle contenant trois principes actifs | |
| HRP20171815T1 (hr) | Stabilni farmaceutski pripravak koji sadrži amorfni rosuvastatin-kalcij |